Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.49 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.47 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.45 |
| ▸ | NPBWR1 | P48145 | 5/20 | 0.45 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.43 |
| ▸ | FLT3 | P36888 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4139643 | 0.90 | SCD (0.52) | SCDHRH4TRPV1PTGDR2NPBWR1 | |
| SCHEMBL4151635 | 0.90 | NPBWR1 (0.56) | NPBWR1 | |
| SCHEMBL4193190 | 0.87 | SCD (0.55) | SCDHRH4TRPV1NPBWR1METAP2 | |
| SCHEMBL4148429 | 0.85 | MMP13 (0.53) | TRPV1PTGDR2HDAC6 | |
| SCHEMBL4154640 | 0.84 | PTGDR2 (0.47) | SCDHRH4TRPV1PTGDR2NPBWR1 | |
| SCHEMBL4150650 | 0.83 | SCD (0.49) | SCDHRH4TRPV1PTGDR2NPBWR1 | |
| SCHEMBL4154972 | 0.83 | SCD (0.49) | SCDHRH4TRPV1PTGDR2NPBWR1 | |
| SCHEMBL4184841 | 0.83 | NPBWR1 (0.57) | SCDTRPV1NPBWR1 | |
| SCHEMBL13741472 | 0.82 | NPC1 (0.52) | HDAC6 | |
| SCHEMBL4146419 | 0.80 | HDAC6 (0.53) | SCDHRH4TRPV1PTGDR2NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | claimed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | claimed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | claimed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | claimed |
| EP-2054405-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-05-06 | — | — | EP | claimed |
| WO-2008007900-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2008-01-17 | — | — | WO | claimed |
| US-8940769-B2 | Biaryl benzoimidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2015-01-27 | — | — | US | disclosed |
| EP-2054405-B1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAE WOONG PHARMA (KR) | 2013-09-18 | — | — | EP | disclosed |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-08-22 | — | — | US | disclosed |
| US-8436022-B2 | Biaryl benzolmidazole derivatives and pharmaceutical composition comprising the same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2013-05-07 | — | — | US | disclosed |
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | DAEWOONG PHARMACEUTICAL CO., LTD. (KR) | 2009-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209540-A1 | Novel Biaryl Benzolmidazole Derivatives and Pharmaceutical Composition Comprising The Same | TRPV1, TRPV3, TRPV5 | SCD 1395/4885HRH4 59/4885TRPV1 1/4885 |
| US-20130217684-A1 | NOVEL BIARYL BENZOIMIDAZOLE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | TRPV1, TRPV3, TRPA1 | SCD 1346/4885HRH4 41/4885TRPV1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.